1. Home
  2. HTBK vs ANAB Comparison

HTBK vs ANAB Comparison

Compare HTBK & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HTBK
  • ANAB
  • Stock Information
  • Founded
  • HTBK 1997
  • ANAB 2005
  • Country
  • HTBK United States
  • ANAB United States
  • Employees
  • HTBK N/A
  • ANAB N/A
  • Industry
  • HTBK Major Banks
  • ANAB Biotechnology: Pharmaceutical Preparations
  • Sector
  • HTBK Finance
  • ANAB Health Care
  • Exchange
  • HTBK Nasdaq
  • ANAB Nasdaq
  • Market Cap
  • HTBK 588.2M
  • ANAB 621.1M
  • IPO Year
  • HTBK 1998
  • ANAB 2017
  • Fundamental
  • Price
  • HTBK $10.24
  • ANAB $22.50
  • Analyst Decision
  • HTBK Buy
  • ANAB Buy
  • Analyst Count
  • HTBK 3
  • ANAB 10
  • Target Price
  • HTBK $11.33
  • ANAB $44.25
  • AVG Volume (30 Days)
  • HTBK 482.2K
  • ANAB 659.2K
  • Earning Date
  • HTBK 07-24-2025
  • ANAB 08-04-2025
  • Dividend Yield
  • HTBK 5.08%
  • ANAB N/A
  • EPS Growth
  • HTBK N/A
  • ANAB N/A
  • EPS
  • HTBK 0.68
  • ANAB N/A
  • Revenue
  • HTBK $174,083,000.00
  • ANAB $111,872,000.00
  • Revenue This Year
  • HTBK $7.71
  • ANAB N/A
  • Revenue Next Year
  • HTBK $6.13
  • ANAB $24.39
  • P/E Ratio
  • HTBK $15.06
  • ANAB N/A
  • Revenue Growth
  • HTBK N/A
  • ANAB 387.20
  • 52 Week Low
  • HTBK $8.09
  • ANAB $12.21
  • 52 Week High
  • HTBK $11.27
  • ANAB $41.31
  • Technical
  • Relative Strength Index (RSI)
  • HTBK 72.82
  • ANAB 45.71
  • Support Level
  • HTBK $9.11
  • ANAB $22.49
  • Resistance Level
  • HTBK $9.81
  • ANAB $24.86
  • Average True Range (ATR)
  • HTBK 0.19
  • ANAB 1.15
  • MACD
  • HTBK 0.07
  • ANAB -0.27
  • Stochastic Oscillator
  • HTBK 91.86
  • ANAB 0.00

About HTBK Heritage Commerce Corp

Heritage Commerce Corp operates as a bank holding company. The company, through its subsidiary, offers commercial banking services to small and medium-sized businesses and their owners, managers, and employees. It operates through two reportable segments, namely Banking and Factoring. A majority of its revenue is generated from the Banking segment, which provides various loan products, including commercial and industrial loans, commercial real estate loans, construction loans, etc. This segment also focuses on deposit generation on relationship accounts, encompassing non-interest bearing demand, interest bearing demand, money market accounts, certificates of deposit, and savings accounts.

About ANAB AnaptysBio Inc.

AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).

Share on Social Networks: